jm5003952_si_001.pdf (108.2 kB)
Serotonin 5‑HT6 Receptor Antagonists for the Treatment of Cognitive Deficiency in Alzheimer’s Disease
journal contribution
posted on 2014-09-11, 00:00 authored by Bellinda Benhamú, Mar Martín-Fontecha, Henar Vázquez-Villa, Leonardo Pardo, María L. López-RodríguezAlzheimer’s
disease (AD) is one of the most frequent causes
of death and disability worldwide and has a significant clinical and
socioeconomic impact. In the search for novel therapeutic strategies,
serotonin 5-HT6 receptor (5-HT6R) has been proposed
as a promising drug target for cognition enhancement in AD. This manuscript
reviews the compelling evidence for the implication of this receptor
in learning and memory processes. We have summarized the current status
of the medicinal chemistry of 5-HT6R antagonists and the
encouraging preclinical findings that demonstrate their significant
procognitive behavioral effects in a number of learning paradigms,
probably acting through modulation of multiple neurotransmitter systems
and signaling pathways. The results of the ongoing clinical trials
are eagerly awaited to shed some light on the validation of 5-HT6R antagonists as a new drug class for the treatment of symptomatic
cognitive impairment in AD, either as stand-alone therapy or in combination
with established agents.